Drug Profile
Research programme: phosphatidylinositol 3-kinase inhibitors - Karus Therapeutics
Alternative Names: KAR-4000; KAR1139; KAR1141; Lipid kinase signaling inhibitors - Karus; PI3K-p110 beta; PI3K-p110 deltaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Karus Therapeutics
- Developer Karus Therapeutics; University of London
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in United Kingdom (PO)
- 17 Dec 2012 Karus Therapeutics enters into a collaboration with the Babraham Institue to further characterise its PI3K inhibitors for inflammatory diseases